<?xml version="1.0" encoding="UTF-8"?>
<p id="p0125">According to a report, it has been reported that arbidol at a concentration range of 10–30 μM 
 <italic>in vitro</italic> is effective against SARS-COV-2 (
 <xref rid="bib103" ref-type="bibr">Chinanews, 2020</xref>). In a clinical study involving 111 patients, it was found that arbidol promotes and strengthens the cycle of viral clearance, enhances focal penetration on radiological images, and decreases demand for the high-flow nasal cannula (HFNC) oxygen therapy in-hospital treatment (
 <xref rid="bib154" ref-type="bibr">Xu et al., 2020a</xref>). In a retrospective analysis, arbidol, in combination with lopinavir/ritonavir, showed beneficial effects (
 <xref rid="bib32" ref-type="bibr">Deng et al., 2020</xref>). Though, in a randomized clinical study involving 240 COVID-19 patients half of which received arbidol and other half received Favipiravir proved that the clinical retrieval rate of day 7 was 55.86% in the arbidol group and 71.43% in the favipiravir group showing the superiority of favipiravir (
 <xref rid="bib16" ref-type="bibr">Chen et al., 2020a</xref>).
</p>
